Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.56 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.54 |
| ▸ | CNR1 | P21554 | 3/20 | 0.49 |
| ▸ | CNR2 | P34972 | 3/20 | 0.49 |
| ▸ | DAO | P14920 | 1/20 | 0.49 |
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.46 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.45 |
| ▸ | CDK4 | P11802 | 3/20 | 0.43 |
| ▸ | CCND1 | P24385 | 3/20 | 0.43 |
| ▸ | CFTR | P13569 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5194675 | 0.89 | P2RX7 (0.52) | MTNR1AP2RX7CNR1CNR2DAO | |
| SCHEMBL7771626 | 0.88 | MTNR1A (0.60) | MTNR1AP2RX7CNR1CNR2DAO | |
| SCHEMBL28057970 | 0.87 | MTNR1A (0.48) | MTNR1AP2RX7CNR1CNR2DAO | |
| SCHEMBL14578714 | 0.84 | MTNR1A (0.56) | MTNR1AP2RX7CNR1CNR2DAO | |
| SCHEMBL9039466 | 0.83 | MTNR1A (0.55) | MTNR1AP2RX7DAOCDK4CCND1 | |
| SCHEMBL30462513 | 0.82 | MTNR1A (0.57) | MTNR1AP2RX7DAOCDK4CCND1 | |
| SCHEMBL8240735 | 0.81 | MTNR1A (0.53) | MTNR1AP2RX7CNR1CNR2DAO | |
| SCHEMBL2543931 | 0.81 | MTNR1A (0.55) | MTNR1AP2RX7DAOKMT2APARP1 | |
| SCHEMBL28057969 | 0.80 | MTNR1A (0.43) | MTNR1AP2RX7CNR1CNR2DAO | |
| SCHEMBL1567707 | 0.79 | HTT (0.51) | CNR1CNR2TLR8CFTRHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4574167-B2 | — | — | 2010-11-04 | — | — | JP | claimed |
| US-7501505-B2 | Activators for oligonucleotide synthesis | AVECIA BIOTECHNOLOGY, INC. (US) | 2009-03-10 | — | — | US | claimed |
| CN-100430411-C | Activators for oligonucleotide synthesis | AVECIA LTD (US) | 2008-11-05 | — | — | CN | claimed |
| US-20060041114-A1 | Activators for oligonucleotide synthesis | NITTO DENKO AVECIA, INC. | 2006-02-23 | — | — | US | claimed |
| EP-1404696-B1 | ACTIVATORS FOR OLIGONUCLEOTIDE SYNTHESIS | AVECIA BIOTECHNOLOGY INC (US) | 2006-02-08 | — | — | EP | claimed |
| CN-1549820-A | Activators for oligonucleotide synthesis | ƽ | 2004-11-24 | — | — | CN | claimed |
| EP-1404696-A1 | ACTIVATORS FOR OLIGONUCLEOTIDE SYNTHESIS | Avecia Biotechnology, Inc. (US) | 2004-04-07 | — | — | EP | claimed |
| WO-2003004512-A1 | ACTIVATORS FOR OLIGONUCLEOTIDE SYNTHESIS | AVECIA BIOTECHNOLOGY INC. (US) | 2003-01-16 | — | — | WO | claimed |
| EP-1501851-B1 | PROCESS FOR PREPARING OLIGONUCLEOTIDES | NITTO DENKO AVECIA INC (US) | 2013-02-13 | — | — | EP | disclosed |
| US-20120035199-A9 | SPIROHETEROCYCLIC COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2012-02-09 | — | — | US | disclosed |
| US-8093397-B2 | Activators for oligonucleotide synthesis | AVECIA BIOTECHNOLOGY, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| EP-1888592-B1 | SPIROHETEROCYCLIC COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2011-04-06 | — | — | EP | disclosed |
| US-20110034500-A1 | SPIROHETEROCYCLIC COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2011-02-10 | — | — | US | disclosed |
| EP-1575975-B1 | PROCESS FOR THE PREPARATION OF OLIGONUCLEOTIDES | AVECIA BIOTECHNOLOGY INC (US) | 2010-10-27 | — | — | EP | disclosed |
| CN-1549820-A | Activators for oligonucleotide synthesis | ƽ | 2004-11-24 | — | — | CN | disclosed |
| WO-2004055036-A1 | PROCESS FOR THE PREPARATION OF OLIGONUCLEOTIDES | AVECIA LIMITED (GB) | 2004-07-01 | — | — | WO | disclosed |
| WO-2004035599-A1 | PHOSPHITYLATION PROCESS | AVECIA BIOTECHNOLOGY INC. (US) | 2004-04-29 | — | — | WO | disclosed |
| EP-1404696-A1 | ACTIVATORS FOR OLIGONUCLEOTIDE SYNTHESIS | Avecia Biotechnology, Inc. (US) | 2004-04-07 | — | — | EP | disclosed |
| WO-2003091267-A1 | PROCESS FOR PREPARING OLIGONUCLEOTIDES | AVECIA LIMITED (GB) | 2003-11-06 | — | — | WO | disclosed |
| WO-2003004512-A1 | ACTIVATORS FOR OLIGONUCLEOTIDE SYNTHESIS | AVECIA BIOTECHNOLOGY INC. (US) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060041114-A1 | Activators for oligonucleotide synthesis | MED12, RBM12, RPS12 | MTNR1A 290/4885P2RX7 552/4885CNR1 386/4885 |
| US-20110034500-A1 | SPIROHETEROCYCLIC COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | SCN3A, SCN1B, SCN2B | MTNR1A 587/4885P2RX7 357/4885CNR1 543/4885 |
| US-20120035199-A9 | SPIROHETEROCYCLIC COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | SCN3A, SCN1B, SCN2B | MTNR1A 587/4885P2RX7 357/4885CNR1 543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.